Back to Search
Start Over
ViiV Healthcare Presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation
- Source :
- Plus Company Updates. March 5, 2024
- Publication Year :
- 2024
-
Abstract
- LONDON: ViiV Healthcare announces positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), can be dosed at intervals of [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.789094829